SFX by Ex Libris Inc.

Title:	Prognosis for patients with CML and 〉10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Source:	Blood [0006-4971] Branford, Susan yr:2014

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Etienne, G. "Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia." Journal of clinical oncology 35.3 (2016): 298-305.
description	2.	Parker, Wendy T. "Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination." Blood 124.1 (2014): 153-5.
description	3.	Olshen A, A. "Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib." Haematologica 99.11 (2014): 1701-1709.
description	4.	"5-HT1A receptors of the rat dorsal raphe lateral wings and dorsomedial subnuclei differentially control anxiety- and panic-related defensive responses." Neuropharmacology 107: 471-479.
description	5.	Rea, D. "Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study." Blood 129.7 (2016): 846-854.
description	6.	Baccarani, M. "A review of the European LeukemiaNet recommendations for the management of CML." Annals of hematology 94.2 (2015): 141-147.
description	7.	Nam, B. "Development and validation of a predictive model to assess an individual's risk of pancreatic cancer." Journal of clinical oncology 2013. 861-9.
description	8.	Le Cesne, A. "Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial." Lancet oncology 11.11 (2010): 942-9.
description	9.	Caramins, Melody C. "Integrating Massively Parallel Sequencing into Diagnostic Workflows and Managing the Annotation and Clinical Interpretation Challenge." Human mutation 35.4 (2014): 413-423.
description	10.	Lydon, B J J. "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells." Nature medicine 2.5 (1996): 561-6.
description	11.	Lipton, Jeffrey H. "Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial." Lancet oncology 17.5 (2016): 612-621.
description	12.	Fava, C. "Chronic Myeloid Leukemia: State of the Art in 2012." Current oncology reports 14.5 (2012): 1-8.
description	13.	Ross, Ross M. "Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR." Leukemia 24.10 (2010): 1719-1724.
description	14.	Fenaux, P. "Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)." Journal of Hematology & Oncology 10.1 (2017): 131-131.
description	15.	"Quality improvement project regarding posttraumatic stress disorder (PTSD) and benzodiazepines as part of the Psychotropic Drug Safety Initiative (PDSI)." Pharmacotherapy : official journal of the American College of Clinical Pharmacy. 36.7.
description	16.	Yang, Hee C. "Recurrence Risk-Scoring Model for Stage I Adenocarcinoma of the Lung." Annals of Surgical Oncology 22.12 (2015): 4089-4097.
description	17.	Klein, Eric A. "Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk." Urology 90 (2016): 148-152.
description	18.	Carrie, C. "Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial." Lancet oncology 17.6 (2016): 747-756.
description	19.	Liu, Y. "Radiomic features are associated with EGFR mutation status in lung adenocarcinomas." Clinical lung cancer 17.5 (2016): 441-448000000.
description	20.	Frick, A. "Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study." Molecular Psychiatry 21.10 (2015): 1400-1407.